The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain ...

Shares of Vertex Pharmaceuticals sank 15% after the drugmaker announced a study showed its experimental pain medicine was not ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $481.56, ...

Vertex Pharmaceuticals ( NASDAQ: VRTX) shares fell in premarket trading on Tuesday after the company's VX-993 failed to meet ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

In connection with earnings, Vertex announced topline results from the Phase 2 study evaluating the safety and efficacy of VX ...

Section 1.10.32 of "de Finibus Bonorum et Malorum", written by Cicero in 45 BC ...

Vertex Pharmaceuticals (VRTX) posts strong Q2 earnings and revenue growth but faces a 17% stock drop after mid-stage pain drug failure. Read more here.

Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any ...

Anthropic says Claude Opus 4.1 improves software engineering accuracy to 74.5%. That compares to 62.3% with Claude Sonnet 3.7 and 72.5% with Claude Opus 4. More specifically, the updated model is ...

IBD 50 and IBD Big Cap 20 name Palantir Technologies PLTR surged around 7% and reached a record high on the stock market today. The company reported better-than-expected second-quarter profit and ...

Hinge Health, which went public in May, reported light second-quarter sales. But the IPO stock popped in late trades Tuesday.